The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury-Reference-Cited by-同舟云学术

The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury

Published:2018-03-27 Issue: Volume:9 Page:
ISSN:1664-042X
Container-title:Frontiers in Physiology
language:
Short-container-title:Front. Physiol.

Author:

Rathinasabapathy Anandharajan,Horowitz Alana,Horton Kelsey,Kumar Ashok,Gladson Santhi,Unger Thomas,Martinez Diana,Bedse Gaurav,West James,Raizada Mohan K.,Steckelings Ulrike M.,Sumners Colin,Katovich Michael J.,Shenoy Vinayak

Funder

National Institutes of Health

American Heart Association

Publisher

Frontiers Media SA

Subject

Physiology (medical),Physiology

Reference37 articles.

1. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice;Anandharajan;Metab. Clin. Exp.,2009

2. Simple method of estimating severity of pulmonary fibrosis on a numerical scale;Ashcroft;J. Clin. Pathol.,1988

3. Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus;Avila;Cell Calcium,2014

4. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis;Bruce;Br. J. Pharmacol.,2015

5. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease;Bullock;Histochem. Cell Biol.,2001

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stimulation of Angiotensin II Receptor Subtype 2 Reduces Preeclampsia-like Symptoms in a Mouse Model of Preeclampsia;Current Issues in Molecular Biology;2024-09-02

2. Structural impact, ligand–protein interactions, and molecular phenotypic effects of TGF-β1 gene variants: In silico analysis with implications for idiopathic pulmonary fibrosis;Gene;2024-09

3. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

4. Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?;Frontiers in Pharmacology;2024-04-10

5. Unlocking the protective potential of the angiotensin type 2 receptor (AT2R) in acute lung injury and age-related pulmonary dysfunction;Biochemical Pharmacology;2024-02